Skip to main content

Main navigation

  • About
    • Members
    • Our Team
    • Annual Report
    • Rutgers-NPC Health Policy & Communications Fellowship
    • NPC Summer Scholars
    • Contact Us
  • Topics
    • Health Spending
      • IRA & Medicare Drug Price Negotiation
      • 340B Drug Pricing Program
      • Understanding Health Spending
      • Low-Value Care
      • Health Spend Management
    • Value Assessment
      • Value Assessment Frameworks
      • Value Assessment Methods
      • Elements of Value
    • Alternative Payment Models
      • Value-Based Contracts
      • Regulatory Barriers & Challenges
      • Paying for Cures
      • Accountable Care Organizations
      • Bundled Payments
      • Health Care Quality Measures
      • Clinical Pathways
    • Patient-Centered Formulary & Benefit Design
      • High-Deductible Health Plans
      • Value-Based Insurance Design
      • Utilization Management & Step Therapy
      • Formulary Development
      • Patient Cost Sharing
      • Individual Treatment Effects & Personalized Access
    • Evidence for Decision Making
      • Real-World Data
      • Real-World Evidence
      • Good Practices for Evidence
    • Biopharma Innovation
      • Impact on Outcomes & Spending
  • Resources
    • Research
    • Fact Sheets
    • Policy & Evidence Briefs
    • Letters & Comments
    • E.V.I.dently Today Blog
    • Newsletters
    • Events
    • CER Daily Newsfeed®
    • Press Room
      • NPC in the News
      • NPC Press Releases
    • Videos and Graphics
    • Stakeholder Resources
      • For Employers
      • For Patient Organizations
      • Going Below The Surface
  • Get Involved
    • Become a Member
    • Submit a Research Proposal
    • Start a Career
  • Members Only
    • Value of Membership
      • Strategic Plan
      • Research Pipeline
    • Member Resources
      • Weekly Leadership Memo
      • Government Price-Setting & IRA Implementation Member Resources
      • Value Assessment & ICER-Related Member Resources
      • Health Spending & Drug Pricing Member Resources
      • Other Policy-Relevant Member Resources
    • Member Events
      • Leadership Forums
    • Board of Directors
    • Committees & Workgroups
      • Audit & Budget
      • Board-Level Research Committee
      • Executive Committee
      • Strategic Advisory Group
      • Corresponding Officers
      • Research Work Group
      • Employer Work Group
      • Policy & Communications Work Group
    • Logout
National Pharmaceutical Council

Offscreen menu

User account menu

  • Member Resources

The CAR T-Cell Therapy Transformation: Understanding the Technology, Current Landscape, and Future Directions

  • Read more about The CAR T-Cell Therapy Transformation: Understanding the Technology, Current Landscape, and Future Directions

How Time Is Accounted for When Modeling Pharmaceutical Impacts: Investment vs. Assessment Perspectives

  • Read more about How Time Is Accounted for When Modeling Pharmaceutical Impacts: Investment vs. Assessment Perspectives

Inflation Reduction Act Impact on Pharmaceutical Investment: Insights From Investor Interviews

  • Read more about Inflation Reduction Act Impact on Pharmaceutical Investment: Insights From Investor Interviews

77% of Investors Say IRA's "Pill Penalty" Disincentivizes Small Molecule Investments

  • Read more about 77% of Investors Say IRA's "Pill Penalty" Disincentivizes Small Molecule Investments

Research Finds That Post-Approval Cancer Trials Fell After IRA Passage, With Disproportionate Impact on Small Molecule Drugs

  • Read more about Research Finds That Post-Approval Cancer Trials Fell After IRA Passage, With Disproportionate Impact on Small Molecule Drugs

Early Impact of the Inflation Reduction Act on Small Molecule vs Biologic Post-Approval Oncology Trials

  • Read more about Early Impact of the Inflation Reduction Act on Small Molecule vs Biologic Post-Approval Oncology Trials

Yevgeniy Feyman, PhD

  • Read more about Yevgeniy Feyman, PhD

House Hearing Highlights NPC Research on IRA Impact on Orphan Drugs

  • Read more about House Hearing Highlights NPC Research on IRA Impact on Orphan Drugs

Whittington, Garrison, and Campbell: Challenges with Judging and Interpreting a Drug’s Launch Price (AJMC Commentary)

  • Read more about Whittington, Garrison, and Campbell: Challenges with Judging and Interpreting a Drug’s Launch Price (AJMC Commentary)

Challenges With Judging and Interpreting a Drug’s Launch Price

  • Read more about Challenges With Judging and Interpreting a Drug’s Launch Price

Pagination

  • Next page
  • Page 2
  • Next page
Subscribe to Biopharmaceutical Innovation

Let's stay in touch.

Subscribe to our newsletter.
© 2026 NPC. All rights reserved.

Footer Menu

  • Accessibility
  • Privacy Policy
  • Terms of Use
  • Contact Us

Footer Social Links Menu

  • Twitter image/svg+xml
  • Linkedin
  • Youtube